ID: ALA3359161

Max Phase: Preclinical

Molecular Formula: C12H11N5OS

Molecular Weight: 273.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc2[nH]c(SCc3ccccc3)nc2c(=O)[nH]1

Standard InChI:  InChI=1S/C12H11N5OS/c13-11-15-9-8(10(18)17-11)14-12(16-9)19-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,13,14,15,16,17,18)

Standard InChI Key:  RHAPVHANDLLSAI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 273.32

Molecular Weight (Monoisotopic): 273.0684

AlogP: 1.52

#Rotatable Bonds: 3

Polar Surface Area: 100.45

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.72

CX Basic pKa:

CX LogP: 1.79

CX LogD: 1.64

Aromatic Rings: 3

Heavy Atoms: 19

QED Weighted: 0.63

Np Likeness Score: -1.27

References

1. Dennis ML, Chhabra S, Wang ZC, Debono A, Dolezal O, Newman J, Pitcher NP, Rahmani R, Cleary B, Barlow N, Hattarki M, Graham B, Peat TS, Baell JB, Swarbrick JD..  (2014)  Structure-based design and development of functionalized Mercaptoguanine derivatives as inhibitors of the folate biosynthesis pathway enzyme 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase from Staphylococcus aureus.,  57  (22): [PMID:25357262] [10.1021/jm501417f]

2. Dennis ML, Pitcher NP, Lee MD, DeBono AJ, Wang ZC, Harjani JR, Rahmani R, Cleary B, Peat TS, Baell JB, Swarbrick JD..  (2016)  Structural Basis for the Selective Binding of Inhibitors to 6-Hydroxymethyl-7,8-dihydropterin Pyrophosphokinase from Staphylococcus aureus and Escherichia coli.,  59  (11): [PMID:27094768] [10.1021/acs.jmedchem.6b00002]

Source

Source(1):

• Scientific Literature